Lung cancer trials in Spain

In Spain 273 Also abroad 2733

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
Where
Alcorcón, Badalona, Sabadell, Hospital de La Santa Creu Isant Pau
Age
18 years and over
People
189 worldwide
Run by
Fondazione Ricerca Traslazionale
See details and how to joinNCT04811001 · EU 2024-518223-29-00
Phase 1Taking people
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
Age
18 years and over
People
554 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Alicante, Barcelona, Jerez de la Frontera, Reus
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Barcelona, Castello De La Plana, Las Palmas de Gran Canaria, Madrid, Majadahonda, Sevilla
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Barcelona, Madrid, Málaga, PAU de Sanchinarro, Pozuelo de Alarcón, Seville, Valencia
Age
18 years and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Barcelona, Logroño, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
A Coruna, Alicante, Barakaldo, Barcelona, Granada, Jerez de la Frontera, Madrid, Santa Cruz de Tenerife, Valencia
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Where
Barcelona, Madrid
Age
18 years and over
People
248 worldwide
Run by
Terremoto Biosciences Inc.
See details and how to joinNCT07109726
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
A Coruña, Alicante, Barcelona, Málaga, Santander, Sevilla
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Santiago de Compostela, Sevilla, Valencia, Vigo
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 1/2Not yet taking people in Spain
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 2Taking people
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Where
Barcelona, Girona, Jaén, Logrono, Lugo, Madrid, Málaga, Pamplona, Santiago de Compostela, Sevilla
Age
18 years and over
People
131 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
A Coruña, Badalona, Barakaldo, Barcelona, Córdoba, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Marbella, Palma, Sevilla
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00 · EU 2023-509340-10-00
Phase 2Taking people
Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
Where
Alicante, Barcelona, Madrid
Age
18 years and over
People
6
Run by
Janssen Cilag International
See details and how to join2025-524816-13-00 · EU 2025-524816-13-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
A Coruña, Barcelona, Burgos, Castello De La Plana, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Oviedo, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Valencia
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 1Taking people
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Where
Barcelona, Madrid, Málaga
Age
18 years and over
People
40 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07140016 · EU 2025-522398-12-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Barakaldo, Barcelona, Jaén, Madrid, Málaga, Murcia
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Badalona, Barcelona, Madrid, Majadahonda, Málaga, Sevilla
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
Phase 1/2Taking people
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga, Pamplona, Sevilla, Torrejón de Ardoz, Valencia
Age
18 years and over
People
880 worldwide
Run by
BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00
Phase 1Not yet taking people in Spain
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 2Taking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
A Coruña, Alicante, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Reus, Sevilla, Terrassa, Valencia
Age
18 years to 95 years
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00